FR2391730A1 - Composition a base d'une resine styrene-divinylbenzene d'echange anionique portant des groupes ammonium quaternaire, destinee a fixer les acides biliaires - Google Patents

Composition a base d'une resine styrene-divinylbenzene d'echange anionique portant des groupes ammonium quaternaire, destinee a fixer les acides biliaires

Info

Publication number
FR2391730A1
FR2391730A1 FR7815132A FR7815132A FR2391730A1 FR 2391730 A1 FR2391730 A1 FR 2391730A1 FR 7815132 A FR7815132 A FR 7815132A FR 7815132 A FR7815132 A FR 7815132A FR 2391730 A1 FR2391730 A1 FR 2391730A1
Authority
FR
France
Prior art keywords
quaternary ammonium
ammonium groups
intended
composition based
anionic exchange
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7815132A
Other languages
English (en)
Other versions
FR2391730B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FR2391730A1 publication Critical patent/FR2391730A1/fr
Application granted granted Critical
Publication of FR2391730B1 publication Critical patent/FR2391730B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition destinée à fixer les acides biliaires. La composition de l'invention contient du carbonate de calcium et une résine d'échange anionique polymère insoluble dans l'eau du type styrène-divinylbenzène et portant des groupes ammonium quaternaire. L'administration dune dose orale quotidienne de cette composition permet de séquestrer les acides biliaires dans l'intestin d'un être humain, sous une forme qui en permet l'excrétion.
FR7815132A 1977-05-23 1978-05-22 Composition a base d'une resine styrene-divinylbenzene d'echange anionique portant des groupes ammonium quaternaire, destinee a fixer les acides biliaires Granted FR2391730A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79984877A 1977-05-23 1977-05-23

Publications (2)

Publication Number Publication Date
FR2391730A1 true FR2391730A1 (fr) 1978-12-22
FR2391730B1 FR2391730B1 (fr) 1980-07-04

Family

ID=25176920

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7815132A Granted FR2391730A1 (fr) 1977-05-23 1978-05-22 Composition a base d'une resine styrene-divinylbenzene d'echange anionique portant des groupes ammonium quaternaire, destinee a fixer les acides biliaires

Country Status (6)

Country Link
JP (1) JPS5417133A (fr)
DE (1) DE2822546A1 (fr)
FR (1) FR2391730A1 (fr)
GB (1) GB1573487A (fr)
IT (1) IT1104841B (fr)
ZA (1) ZA782729B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012351A1 (fr) * 1996-09-19 1998-03-26 Roth W Kurt Procede de purification et eventuellement d'analyse d'acides nucleiques contenus dans des echantillons biologiques
WO1998042355A1 (fr) * 1997-03-25 1998-10-01 Geltex Pharmaceuticals, Inc. Polymeres liant le phosphate, combines a un supplement de calcium et administres par voie orale

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4804548A (en) * 1984-10-05 1989-02-14 Warner-Lambert Company Novel sweetener delivery systems
US4828857A (en) * 1984-10-05 1989-05-09 Warner-Lambert Company Novel sweetener delivery systems
US4851392A (en) * 1985-02-05 1989-07-25 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4790991A (en) * 1985-02-05 1988-12-13 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4818539A (en) * 1985-02-05 1989-04-04 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4843098A (en) * 1985-02-05 1989-06-27 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
US5167965A (en) * 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
CA2129079C (fr) * 1993-08-03 2006-01-17 Tatsuo Nomura Hypocholesterolemiant pour administration par voie orale
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2007027566A2 (fr) 2005-09-02 2007-03-08 Genzyme Corporation Recepteurs moleculaires polymeriques utilises comme sequestrants du phosphate
PT1924246E (pt) 2005-09-15 2016-02-10 Genzyme Corp Formulação sachê para polímeros com funcionalidade amina
RU2591188C2 (ru) 2010-11-08 2016-07-10 Альбирео Аб Ингибиторы ibat для лечения заболеваний печени
CA2952406A1 (fr) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Preparation solide et procede d'inhibition ou d'attenuation de coloration de celle-ci
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2019032026A1 (fr) 2017-08-09 2019-02-14 Albireo Ab Granules de cholestyramine, formulations orales de cholestyramine et leur utilisation
WO2019167080A1 (fr) * 2018-03-01 2019-09-06 Olene Life Sciences Private Limited Composition de séquestration d'acide biliaire de chélate de résine et son procédé de préparation
EP3802504B1 (fr) 2018-06-05 2023-01-18 Albireo AB Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11802115B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
IL293379A (en) 2019-12-04 2022-07-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (fr) 2020-08-03 2022-02-10 Per-Goran Gillberg Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2428639A1 (de) * 1973-06-15 1975-01-09 Bristol Myers Co Therapeutische mittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2428639A1 (de) * 1973-06-15 1975-01-09 Bristol Myers Co Therapeutische mittel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012351A1 (fr) * 1996-09-19 1998-03-26 Roth W Kurt Procede de purification et eventuellement d'analyse d'acides nucleiques contenus dans des echantillons biologiques
WO1998042355A1 (fr) * 1997-03-25 1998-10-01 Geltex Pharmaceuticals, Inc. Polymeres liant le phosphate, combines a un supplement de calcium et administres par voie orale

Also Published As

Publication number Publication date
FR2391730B1 (fr) 1980-07-04
DE2822546A1 (de) 1978-12-07
IT7849461A0 (it) 1978-05-19
JPS5417133A (en) 1979-02-08
ZA782729B (en) 1979-06-27
IT1104841B (it) 1985-10-28
GB1573487A (en) 1980-08-28

Similar Documents

Publication Publication Date Title
FR2391730A1 (fr) Composition a base d'une resine styrene-divinylbenzene d'echange anionique portant des groupes ammonium quaternaire, destinee a fixer les acides biliaires
ATE21481T1 (de) Neue orale mopidamolformen.
DE69531613D1 (de) Einführung einer thiol-gruppe in proteine für die radioimmundetektion und radioimmuntherapie auf der basis von radionukliden
DE69210011D1 (de) Neue Insulinanaloge geeignet für die transdermale Anwendung
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
HUP9900337A2 (hu) Omega-3-Politelítetlen savak orális adagolási formái gyulladásos bélbetegségek kezelésére
FR2444064A1 (fr) Melange de polymere du chlorure de vinyle et de polyetherurethane a groupe amine tertiaire et/ou ammonium, notamment pour objet conforme a usage medical
SE8904087D0 (sv) Peptide derivates
BE882833A (fr) Sels mixtes d'acides amines essentiels ou semi-essentiels et de leurs analogues exempts d'azote, en utilisant pour traiter des desordres renaux
DE69320646T2 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE19975013I1 (de) 2.Oxo-Imidazolidin-Verbindungen Verfahren zu derenHerstellung und pharmazeutische Zusammensetzung
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
DZ452A1 (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-paptide humain.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
FR2355807A1 (fr) Derives d'acides isophtalamiques iodes et agents de contraste qui en contiennent
OA09439A (fr) "Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent".
TNSN98124A1 (fr) Compositions de sertraline solubilisee
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
FR2511866B1 (fr) Formulations pharmaceutiques de pro-insuline humaine
TNSN98193A1 (fr) Formes polymorphes de dofetilide, procede pour leur preparation et composition les contenant
FR2763071B1 (fr) Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
IT8223733A0 (it) Preparazione e composizione derivato terapeutica che lo contiene. dell'isopropilamino-pirimidina, sua
ES265589Y (es) "disposicion perfeccionada de soporte para expositores de impresiones graficas".
ATE29663T1 (de) Kombinierte pharmazeutische zusammensetzung und zugehoeriges verfahren.
IT8221553A0 (it) Composizioni farmaceutiche adattivita' antineoplastica.

Legal Events

Date Code Title Description
ST Notification of lapse